JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $149
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst John Stansel has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $148 to $149.
November 17, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Quest Diagnostics' price target has been raised from $148 to $149 by JP Morgan, while maintaining a Neutral rating.
The increase in price target by JP Morgan is marginal, suggesting a slight positive sentiment but the overall neutral rating indicates that the analyst does not see significant upside or downside potential in the short term. Therefore, the impact on the stock price is likely to be limited.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100